𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

✍ Scribed by Mikkael A. Sekeres; Jaroslaw P. Maciejewski; Harry P. Erba; Manuel Afable; Ricki Englehaupt; Ronald Sobecks; Anjali Advani; Sherry Seel; Josephine Chan; Matt E. Kalaycio

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
164 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase 1-2 study of a farnesyltransfera
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 221 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2

Results of imatinib mesylate therapy in
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated